AngioDynamics (ANGO) Tops Q4 EPS by 3c; Affirms FY18 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- AI stocks lift Wall St as oil falls, Treasury yields decline
AngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results
July 18, 2017 6:00 AM EDTCompany posts record full-year adjusted EPS and Free Cash Flow and issues FY2018 Financial Guidance
Q4 net sales of $86.9 million, down 7% year-over-yearQ4 GAAP loss per share of $0.30; adjusted EPS of $0.19Full Year net sales of $349.6 million, down 1% year-over-yearFull Year GAAP earnings per share of $0.19; Adjusted EPS of $0.73, up 22% compared to FY2016Full Year operating cash generation of $55.7 million; free cash flow generation of $52.7 millionALBANY, N.Y., July 18, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive... More
